Novo Nordisk has launched its once-weekly diabetes and weight-management drug Ozempic in India. The semaglutide-based GLP-1 agonist improves glycaemic control, supports weight loss and may reduce cardiovascular and kidney risks. Prices start at Rs 8,800 per month for the lowest dose
Novo Nordisk will cut 9,000 jobs worldwide—11% of its workforce—by 2026 to save $1.3 billion. The move comes amid rising competition in obesity drugs, slowing sales of Wegovy and Ozempic, and a push to focus on R&D and agility
The undertaking to Delhi HC follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories and OneSource Speciality Pharma. Novo Nordisk’s blockbuster weight-loss drug Ozempic Wegovy is expected to be launched soon in India
The study conducted by the Danish pharma giant showed that the risk reductions were evident soon after initiation, suggesting an effect of semaglutide 2.4 mg beyond weight loss alone.
